In conclusion, our findings suggest that combining a PD-1/L-1 inhibitor with chemotherapy in advanced iCCA treatment has higher anti-tumor efficacy compared to chemotherapy alone therapy. This evidence concerns the gene PDCD1 and neoplasm.